Suglat (ipragliflozin; Astellas/Kotobuki Pharmaceutical/Merck & Co) is a competitive inhibitor of sodium-glucose cotransporter-2 (SGLT-2), approved for the treatment of type 2 diabetes. Inhibition of SGLT-2 prevents reabsorption of glucose in the proximal tubule of the kidney, thus resulting in glucose excretion in the urine. As is the case with other SGLT-2 inhibitors, Suglat’s pharmacological effect is independent of insulin secretion. It can, therefore, be used as an add-on therapy to metformin, pioglitazone, and insulin.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Suglat : Diabetes type 2
LIST OF FIGURES
12 Figure 1: Suglat for type 2 diabetes – SWOT analysis
13 Figure 2: Datamonitor Healthcare drug assessment of Suglat
14 Figure 3: Datamonitor Healthcare drug assessment scorecard for Suglat compared to Januvia
16 Figure 4: Suglat sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Suglat drug profile
6 Table 2: Overview of Suglat Phase III clinical trials
11 Table 3: Available Phase III trial data for Suglat
17 Table 4: Suglat sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.